Obesity and metabolic syndrome, known as pro-atherosclerotic conditions, lead to a significant change in the ratio of adiponectin to LDL in the blood, presumably resulting in increasing the probability of LDL binding to T-cadherin, which can trigger adverse effects. Here, ADIPOQ is linked to obesity disorder.